Cybersecurity exposure Novocure recently disclosed a cybersecurity incident that exposed some patient and contact data. This creates an opening to discuss secure data handling solutions, incident response services, and enhanced patient data privacy assurances for their oncology operations and clinical trials.

Investor engagement Upcoming investor events indicate ongoing capital markets activity and visibility with institutional investors. This presents an opportunity to offer comprehensive communications platforms, investor relations technology, and secure data analytics to support disclosures and investor presentations.

Clinical expansion Novocure is actively pursuing trials in glioblastoma, non-small cell lung cancer and pancreatic cancer. There is potential to offer collaborative research tools, clinical trial data management, imaging analytics, and real-world evidence solutions to streamline trial workflows.

Technology stack fit With a modern tech stack including Google Cloud, ELK, Power Platform and Jira, there are opportunities to propose cloud-native analytics, data integration, security hardening, and workflow automation to improve R&D and commercialization efficiency.

Market positioning As a global oncology-focused medical device company with steady revenue and positive momentum from analysts, there is room to discuss scalable manufacturing and supply chain software, remote monitoring, and customer enablement tools to support international sales and service coverage.